T-cell-prolymphocytic Leukemia — Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)
Citation(s)
Phase II Trial of Combined Immunochemotherapy With Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients With Previously Treated or Untreated T-Prolymphocytic Leukemia